Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith S Currier

Showing results (141-150 of 325) with videos related to

Pageof 33
Sort By:
The Journal of Infectious Diseases|February 6, 2020
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The Journal of Clinical Endocrinology and Metabolism|September 9, 2021
Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHSJennifer Jao, Lauren C Balmert, Shan Sun, et al.
The Journal of Infectious Diseases|May 8, 2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The New England Journal of Medicine|April 26, 2018
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-EmtricitabineKathryn Rough, George R Seage, Paige L Williams, et al.
Antiviral Therapy|November 13, 2004
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patientsJulie M Yasuda, Chris Miller, Judith S Currier, et al.
The Journal of Infectious Diseases|June 30, 2016
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260sTheodoros Kelesidis, Carlee Moser, James H Stein, et al.
AIDS Research and Human Retroviruses|December 25, 2012
Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, BrazilJosé H Pilotto, Beatriz Grinsztejn, Valdilea G Veloso, et al.
Antiviral Therapy|September 24, 2016
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260sTheodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, et al.
AIDS Patient Care and Stds|July 25, 2012
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophyJordan E Lake, Grace A McComsey, Todd M Hulgan, et al.
Topics in Antiviral Medicine|February 17, 2017
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and CareConstance A Benson, Judith S Currier, Carlos Del Rio, et al.
Pageof 33

Showing results (141-150 of 325) with videos related to

Sort By:
Pageof 33
The Journal of Infectious Diseases|February 6, 2020
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The Journal of Clinical Endocrinology and Metabolism|September 9, 2021
Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHSJennifer Jao, Lauren C Balmert, Shan Sun, et al.
The Journal of Infectious Diseases|May 8, 2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The New England Journal of Medicine|April 26, 2018
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-EmtricitabineKathryn Rough, George R Seage, Paige L Williams, et al.
Antiviral Therapy|November 13, 2004
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patientsJulie M Yasuda, Chris Miller, Judith S Currier, et al.
The Journal of Infectious Diseases|June 30, 2016
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260sTheodoros Kelesidis, Carlee Moser, James H Stein, et al.
AIDS Research and Human Retroviruses|December 25, 2012
Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, BrazilJosé H Pilotto, Beatriz Grinsztejn, Valdilea G Veloso, et al.
Antiviral Therapy|September 24, 2016
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260sTheodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, et al.
AIDS Patient Care and Stds|July 25, 2012
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophyJordan E Lake, Grace A McComsey, Todd M Hulgan, et al.
Topics in Antiviral Medicine|February 17, 2017
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and CareConstance A Benson, Judith S Currier, Carlos Del Rio, et al.
Pageof 33